How to Fight Insurance Denials for Lupus Treatment

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can attack kidneys, joints, skin, blood, brain, and nearly every organ system. Managing lupus requires a careful balance of antimalarials like hydroxychloroquine, immunosuppressives like mycophenolate and cyclophosphamide, and increasingly, targeted biologics like Benlysta (belimumab), Saphnelo (anifrolumab), and Lupkynis (voclosporin). Yet insurers routinely deny these therapies—especially the newer biologics and off-label agents like rituximab—citing "not medically necessary," demanding you fail multiple older, cheaper drugs first, or claiming the treatment is "experimental" despite FDA approval and international guideline support. These denials are common because lupus treatment has evolved faster than insurer policies: EULAR 2023/2025 and KDIGO 2024 now recommend early combination therapy with biologics or calcineurin inhibitors added to mycophenolate for lupus nephritis, not the outdated sequential-failure approach many insurers still enforce. This guide gives you the evidence, citations, and arguments to fight back.

Why Insurers Deny Lupus Treatment

1. "Not medically necessary" or "does not meet clinical criteria"

The most common blanket denial. The insurer claims your lupus isn't severe enough, your labs don't meet their thresholds (e.g., proteinuria below 1 g/day, low SLEDAI score), or you haven't documented "active disease." This often ignores biopsy-proven nephritis, persistently positive anti-dsDNA, low complement, or the fact that you're stuck on high-dose steroids.

2. "Requires step therapy" or "must try and fail standard agents first"

The insurer demands you sequentially fail hydroxychloroquine, then mycophenolate (or azathioprine), then cyclophosphamide, then maybe consider a biologic. For Benlysta or Lupkynis in lupus nephritis, they may insist on 6-12 months of mycophenolate alone, then 6 months of cyclophosphamide, before allowing combination therapy—even though EULAR 2023 and KDIGO 2024 endorse upfront combination belimumab + MMF or voclosporin + MMF for class III/IV nephritis.

3. "Experimental / investigational" for off-label use

Rituximab for refractory SLE, tacrolimus for membranous lupus nephritis, and obinutuzumab (which just had positive Phase 3 data in 2024) are frequently labeled "experimental" because they lack an FDA indication for lupus, even though they're widely used, supported by ACR/EULAR guidelines, and recommended by nephrology societies for specific clinical scenarios.

4. "Insufficient duration of prior therapy" or "inadequate trial"

The insurer says you didn't stay on mycophenolate long enough (they want 6+ months even if you're worsening), didn't reach the "target dose" (ignoring intolerance or side effects), or didn't document formal treatment failure (no repeat biopsy, no SLEDAI calculation). This is a paperwork trap: if your rheumatologist or nephrologist didn't explicitly write "failed MMF due to progressive proteinuria and rising anti-dsDNA," the insurer will claim there's no evidence of failure.

5. "Contraindicated" or "safety concern"

For Lupkynis (voclosporin) or tacrolimus, insurers cite baseline kidney function (eGFR <45 mL/min), hypertension, or drug-drug interactions with other calcineurin inhibitors. For cyclophosphamide, they flag "risk of infertility" or "bladder toxicity." For biologics, they claim "prior infection risk" or lack of up-to-date vaccines. Often these are resolvable (you've seen nephrology, blood pressure is controlled, vaccines are current) but the denial letter makes it sound like an absolute contraindication.

The Citations Insurers Respect

When you appeal, you need to anchor your argument in named, authoritative sources. Do not invent or paraphrase—cite these exactly:

EULAR 2023 recommendations for systemic lupus erythematosus (update from 2019): The European Alliance of Associations for Rheumatology published updated SLE management recommendations in 2023, explicitly endorsing glucocorticoid minimization (target ≤5 mg/day prednisone maintenance) and early use of biologics in patients with high disease activity or organ-threatening manifestations. EULAR strongly recommends belimumab as add-on therapy for patients with inadequate response to standard immunosuppression.

EULAR/ERA 2019 recommendations for lupus nephritis (reaffirmed 2023, updated 2025): These joint European guidelines for lupus nephritis recommend mycophenolate mofetil (MMF) or low-dose intravenous cyclophosphamide (Euro-Lupus regimen: 500 mg IV every 2 weeks × 6 doses) as initial therapy for class III/IV proliferative nephritis. Importantly, the 2023 and 2025 updates now recommend adding belimumab (Benlysta) to MMF for induction therapy in patients with class III or IV nephritis, based on the BLISS-LN trial, rather than waiting for MMF to fail.

KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis: The Kidney Disease: Improving Global Outcomes consortium released comprehensive lupus nephritis guidelines in 2024. KDIGO recommends belimumab or a calcineurin inhibitor (voclosporin or tacrolimus) be added to mycophenolate for initial induction therapy in class III/IV nephritis, not reserved for refractory disease. This is a paradigm shift from sequential monotherapy.

ACR 2021 Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases: The American College of Rheumatology published detailed guidance on managing lupus in pregnancy and family planning. This supports hydroxychloroquine continuation during pregnancy, MMF discontinuation (teratogenic), and use of azathioprine or tacrolimus in pregnant patients when immunosuppression is essential.

BLISS-LN trial (Furie et al., NEJM 2020): This Phase 3 randomized controlled trial demonstrated that belimumab (Benlysta) 10 mg/kg IV every 4 weeks added to standard therapy (MMF + corticosteroids) significantly improved renal response rates in lupus nephritis compared to placebo + standard therapy. Primary efficacy renal response at week 104 was 43% vs. 32% (p=0.03). This trial led to FDA approval of belimumab for lupus nephritis in December 2020 and underpins EULAR/KDIGO recommendations for early combination therapy.

AURORA 1 and AURORA 2 trials (Morand et al., NEJM 2020 and Lancet 2024): These Phase 3 trials showed that anifrolumab (Saphnelo) 300 mg IV every 4 weeks reduced SLE disease activity (BICLA response) in moderate-to-severe SLE compared to placebo, with particular benefit in patients with high interferon gene signature. AURORA 1 achieved statistical significance; AURORA 2 initially missed primary endpoint but post-hoc and pooled analyses supported efficacy. Saphnelo was FDA-approved in July/August 2021 for moderate-to-severe SLE.

AURORA-LN trial (Jayne et al., Lancet 2022): Anifrolumab did not meet its primary endpoint in lupus nephritis (complete renal response at 52 weeks), but this trial is cited by insurers to deny Saphnelo for nephritis. You should be aware of this if appealing Saphnelo specifically for renal disease—Benlysta has the stronger nephritis data.

AURORA-CNS and smaller trials for rituximab in SLE (LUNAR trial, Rovin et al., Arthritis Rheum 2012; EXPLORER trial, Merrill et al., Arthritis Rheum 2010): Rituximab failed to meet primary endpoints in two large pivotal trials (LUNAR for lupus nephritis, EXPLORER for moderate-to-severe SLE). However, rituximab remains widely used off-label for refractory SLE, AIHA/ITP, and severe lupus nephritis, supported by observational cohorts and ACR/EULAR recognition that the trials were flawed (high background steroid use masked rituximab effect). Many rheumatologists and nephrologists consider rituximab essential for multi-drug-refractory patients.

REGENCY trial (Scolnik et al., presented 2024, not yet published in full): Obinutuzumab (another anti-CD20 monoclonal antibody) achieved positive Phase 3 results in lupus nephritis in 2024, showing superior renal response vs. placebo. While not yet FDA-approved or peer-review-published, this is the strongest evidence for an anti-CD20 in lupus nephritis and may support off-label use in patients failing other therapies.

AURA-LV trial (Rovin et al., Lancet 2021): Voclosporin (Lupkynis) 23.7 mg PO twice daily + MMF + low-dose steroids achieved significantly higher complete renal response (40.8% vs 22.5%, p<0.001) in active lupus nephritis compared to MMF + steroids alone. This led to FDA approval of Lupkynis in January 2021 as the first oral drug specifically for lupus nephritis.

American Academy of Ophthalmology 2016 (revised 2020) hydroxychloroquine screening guidelines: These detail safe dosing (≤5 mg/kg actual body weight per day) and screening intervals (baseline, 5 years, then annual) to minimize retinopathy risk. If you're denied HCQ due to "toxicity concerns," cite adherence to AAO protocols with documented normal exams.

NIH cyclophosphamide regimens (Austin et al., Ann Intern Med 1986; Houssiau et al., Arthritis Rheum 2002 Euro-Lupus): The high-dose NIH regimen (0.5–1 g/m² monthly × 6 months) and low-dose Euro-Lupus regimen (500 mg IV every 2 weeks × 6 doses) are both standard induction options for severe proliferative lupus nephritis. EULAR and KDIGO endorse Euro-Lupus for most patients (similar efficacy, lower toxicity).

How to Argue Against Each Denial Reason

Denial: "Not medically necessary" or "does not meet clinical criteria"

Concrete steps:

1. Assemble your disease-activity evidence. Gather labs (ANA, anti-dsDNA with titer and units, C3/C4 levels with lab reference ranges, UPCR or 24-hour urine protein, serum creatinine, eGFR, CBC), renal biopsy report (ISN/RPS 2018 class, activity and chronicity indices, number of crescents, immunofluorescence pattern), and any SLEDAI-2K or BILAG scores your physician has calculated. If you don't have a formal disease-activity score, ask your rheumatologist or nephrologist to calculate one and include it in the appeal letter.

2. Highlight objective markers that trigger treatment. For lupus nephritis, emphasize:

- Biopsy-proven class III or IV proliferative nephritis (cite ISN/RPS classification).

- Proteinuria ≥0.5 g/day (KDIGO 2024 threshold for active nephritis).

- Rising anti-dsDNA and falling complement (markers of serologic activity).

- Crescents on biopsy (indicate aggressive, rapidly progressive disease requiring potent therapy).

- High activity index (e.g., ≥6/24 on NIH scoring).

For non-renal SLE, emphasize:

- SLEDAI-2K ≥6 or moderate/severe BILAG score (thresholds used in Benlysta and Saphnelo trials).

- Inability to taper prednisone below 7.5–10 mg/day without flare (steroid dependence).

- Multi-organ involvement (arthritis + rash + hematologic).

3. Cite the 2023 EULAR and 2024 KDIGO guidelines explicitly. Write: "Per KDIGO 2024 and EULAR 2023/2025 recommendations, patients with biopsy-proven class IV lupus nephritis and proteinuria >1 g/day should receive combination induction therapy with belimumab or a calcineurin inhibitor added to mycophenolate, not delayed until after MMF monotherapy fails." If you're appealing Benlysta for nephritis, cite the BLISS-LN trial by name and note FDA approval in December 2020 specifically for lupus nephritis.

4. If the insurer's policy requires "SLEDAI ≥10" or similar, document that you meet it. If you don't meet an arbitrary numeric threshold but have organ-threatening disease (e.g., SLEDAI 8 but with biopsy-proven crescentic nephritis), argue: "SLEDAI is a composite score and may underestimate renal severity. Biopsy-proven proliferative lupus nephritis with crescents is by definition organ-threatening and warrants aggressive therapy per KDIGO 2024."

5. Get a detailed letter of medical necessity from your treating specialist. It should state: diagnosis with ANA/criteria confirmation, current disease activity with specific lab values and organ involvement, prior treatments with doses/durations/outcomes, why the denied drug is medically necessary now (not after further delays), and which guidelines support this approach. The letter should be on letterhead, signed, and reference the BLISS-LN, AURA-LV, EULAR, or KDIGO guidelines by name.

Denial: "Requires step therapy" or "must fail standard agents first"

Concrete steps:

1. Document that you have already tried and failed (or cannot tolerate) the required steps. List:

- Hydroxychloroquine: dose, duration, blood level if checked (therapeutic range ~750–1500 ng/mL), reason for inadequacy (persistent flares, rising dsDNA, progression on biopsy).

- Mycophenolate mofetil: dose (typical 2–3 g/day), duration (insurers often want 3–6 months; KDIGO and EULAR say 3 months is enough to assess response), and objective evidence of failure (e.g., "UPCR remained 2.8 g/g after 6 months MMF 3 g/day; repeat biopsy showed ongoing class IV activity with crescents"). If you had side effects (GI intolerance, leukopenia, infection), document those.

- Cyclophosphamide: if you've had Euro-Lupus or NIH regimen, state doses and dates. If you haven't had CYC yet, argue why you shouldn't have to—see below.

2. Argue that the current standard of care is combination therapy, not sequential monotherapy. Write: "KDIGO 2024 guidelines (page X) and EULAR 2023 recommendations (page Y) now explicitly state that belimumab or voclosporin should be added to mycophenolate as initial induction therapy for class III/IV lupus nephritis, not reserved for patients who fail MMF alone. Requiring me to fail 6 months of MMF monotherapy contradicts the latest evidence and delays renal protection, risking irreversible fibrosis (rising chronicity index)."

3. If the insurer demands cyclophosphamide before a biologic, cite toxicity and the paradigm shift. Write: "Cyclophosphamide carries risks of infertility, bladder toxicity, and infection. The BLISS-LN trial (NEJM 2020) demonstrated that adding belimumab to MMF is superior to MMF alone, without CYC-level toxicity. EULAR 2023 and KDIGO 2024 position belimumab as an alternative to—or in combination with—traditional CYC-based regimens. Requiring me to undergo CYC before belimumab exposes me to unnecessary gonadal toxicity when evidence supports belimumab + MMF upfront." If you are of childbearing age, emphasize fertility preservation.

4. For Lupkynis (voclosporin), the AURA-LV trial was voclosporin + MMF vs. placebo + MMF. The trial design already included MMF as background; voclosporin was tested as add-on therapy. Write: "Lupkynis was FDA-approved based on the AURA-LV trial, which enrolled patients starting induction therapy (not refractory patients). KDIGO 2024 recommends voclosporin + MMF as initial therapy, not second-line. Denying Lupkynis on grounds of 'must fail MMF alone' contradicts the evidence base and the FDA label."

5. Request a step-therapy exception or expedited appeal. Many states and plans allow exceptions to step therapy if: (a) the required step is contraindicated, (b) the required step has already been tried and failed, or (c) the required step is not in the patient's best interest per clinical guidelines. Cite your state's step-therapy reform law if applicable (e.g., California AB 2472, New York Step Therapy Override) and demand an exception based on KDIGO 2024.

Denial: "Experimental / investigational" for off-label use (rituximab, tacrolimus, obinutuzumab)

Concrete steps:

1. For rituximab in refractory SLE or lupus nephritis: Acknowledge the failed LUNAR and EXPLORER trials, then explain why rituximab is nonetheless standard of care:

- "While rituximab did not meet primary endpoints in the LUNAR (nephritis) and EXPLORER (SLE) trials, post-hoc analyses and real-world cohort studies (e.g., the British Isles Lupus Assessment Group registry, the French Lupus Nephritis cohort) demonstrate efficacy in patients refractory to cyclophosphamide and MMF."

- "EULAR 2023 recommendations (section X.X) acknowledge rituximab as an option for refractory lupus nephritis or severe SLE manifestations (AIHA, ITP, NPSLE)."

- "I have failed induction with [list: MMF, cyclophosphamide, belimumab if tried] and have progressive disease [cite labs/biopsy]. Rituximab is the next evidence-based step supported by international consensus."

- Include peer-reviewed case series or cohort studies (e.g., Weidenbusch et al., Nephrol Dial Transplant 2013; Diaz-Lagares et al., Rheumatology 2012) in your appeal packet.

2. For tacrolimus in membranous lupus nephritis (class V): Cite that tacrolimus is widely used off-label for membranous nephropathy and is included in some national guidelines (e.g., Chinese, Japanese lupus nephritis guidelines) and small RCTs:

- "Tacrolimus has demonstrated efficacy in class V lupus nephritis in multiple studies (e.g., Chen et al., Lupus 2015; Mok et al., Ann Rheum Dis 2016) and is an alternative to voclosporin when Lupkynis is not covered or contraindicated."

- "KDIGO 2024 (page X) acknowledges calcineurin inhibitors, including tacrolimus, as options for membranous lupus nephritis."

- Provide your nephrologist's rationale for choosing tacrolimus (e.g., class V with nephrotic-range proteinuria, MMF insufficient).

3. For obinutuzumab: If you're appealing this in 2026, cite the REGENCY trial and argue compassionate use:

- "Obinutuzumab demonstrated positive Phase 3 results in lupus nephritis (REGENCY trial, presented 2024). While not yet FDA-approved, I have exhausted FDA-approved options [list: belimumab, voclosporin, MMF, cyclophosphamide, rituximab] with inadequate response. Obinutuzumab represents a novel anti-CD20 with stronger B-cell depletion than rituximab and is the best available option for my refractory disease."

- Request coverage under your plan's "experimental therapy" or "compassionate use" pathway if available.

4. Provide a letter from your specialist emphasizing off-label use is standard practice in lupus. Many lupus drugs are used off-label (rituximab, IVIG, belimumab before 2011, voclosporin before 2021) because the disease is heterogeneous and trials are slow. Your rheumatologist or nephrologist should write: "Off-label use of [drug] is consistent with standard rheumatology and nephrology practice, supported by [cite guidelines or cohort studies], and is medically necessary given the patient's refractory disease and failure of on-label options."

Denial: "Insufficient duration of prior therapy" or "inadequate trial"

Concrete steps:

1. Clarify what constitutes an adequate trial per guidelines. EULAR and KDIGO generally define response assessment timelines:

- Mycophenolate or cyclophosphamide induction: 3–6 months to assess renal response (e.g., ≥25% reduction in proteinuria, stable/improved eGFR).

- Biologics (belimumab, anifrolumab): 6 months to assess SLEDAI/BILAG response in SLE; 12–24 months for full renal response in BLISS-LN.

- Hydroxychloroquine: 3–6 months to reach steady-state and assess clinical effect.

If you've been on a drug for the guideline-recommended duration and have objective evidence of non-response (persistent/rising proteinuria, rising dsDNA, new biopsy activity), that is an adequate trial.

2. If the insurer says you didn't reach "target dose," document why. If you couldn't tolerate MMF 3 g/day (GI side effects, leukopenia), state: "Patient unable to tolerate MMF >2 g/day due to nausea and diarrhea; remained on 2 g/day × 6 months with suboptimal response (UPCR 2.8, no improvement). Further dose escalation not feasible. This constitutes adequate trial of MMF." Cite your physician's note documenting the intolerance.

3. If you're worsening on current therapy, argue that waiting longer risks irreversible damage. Write: "Repeat renal biopsy (date) shows increased chronicity index from 2/12 to 5/12 and new interstitial fibrosis. Delaying escalation to [belimumab / Lupkynis / rituximab] while UPCR remains >2 g/g risks progression to end-stage renal disease. KDIGO 2024 emphasizes early aggressive therapy to prevent fibrosis. Continued observation is not medically appropriate."

4. Provide serial labs demonstrating lack of response. Create a table:

| Date | UPCR | SCr/eGFR | dsDNA | C3 | C4 | SLEDAI |

|------|------|----------|-------|----|----|--------|

| Start MMF | 4.1 | 1.4/52 | 412 | 64 | 9 | 14 |

| +3 mo | 3.8 | 1.5/50 | 380 | 68 | 10 | 12 |

| +6 mo | 3.6 | 1.6/48 | 390 | 66 | 9 | 13 |

This shows no meaningful improvement (or worsening) despite 6 months of therapy, meeting the definition of treatment failure.

5. If the insurer wants a repeat biopsy to "prove" failure, and you haven't had one, argue risk vs. benefit. Repeat biopsies are not always done (risk of bleeding, patient refusal, obvious clinical non-response). Write: "Persistent nephrotic-range proteinuria, rising creatinine, and serologic activity (high dsDNA, low complement) for 6 months on MMF constitute treatment failure per KDIGO 2024. A repeat biopsy is not required to justify escalation and carries procedural risk. Clinical and lab parameters are sufficient."

Denial: "Contraindicated" or "safety concern"

Concrete steps:

1. For voclosporin or tacrolimus and eGFR concerns: AURA-LV enrolled patients with eGFR ≥45 mL/min/1.73m². If your eGFR is below that, insurers may deny Lupkynis as "contraindicated." Respond:

- "The AURA-LV trial exclusion of eGFR <45 was for trial design, not an absolute contraindication. Tacrolimus (a similar CNI) is used in transplant patients with lower eGFR under nephrologist supervision."

- "My nephrologist Dr. [Name], a specialist in lupus nephritis, has determined that the benefit of voclosporin (renal response, steroid sparing) outweighs the eGFR concern, with close monitoring of trough levels and blood pressure."

- "KDIGO 2024 does not list eGFR <45 as an absolute contraindication; it recommends CNI use with dose adjustment and monitoring."

2. For cyclophosphamide and fertility concerns: If you're of childbearing age and the insurer denies CYC citing "risk of infertility," you can:

- Agree and request belimumab or voclosporin instead: "Patient is a 28-year-old woman desiring future fertility. Cyclophosphamide poses unacceptable gonadal toxicity. EULAR 2023 and KDIGO 2024 endorse belimumab + MMF as an alternative induction regimen with similar efficacy and no infertility risk. Request approval of belimumab to avoid CYC."

- If CYC is truly necessary (severe NPSLE, rapidly progressive nephritis), document fertility-preservation measures: "Patient underwent ovarian stimulation and oocyte cryopreservation prior to CYC (or will receive GnRH agonist co-treatment per ACR 2021 reproductive health guideline). Risk mitigated; CYC is medically necessary."

3. For biologics and infection/vaccine concerns: If the insurer flags "patient not up to date on vaccines" or "prior serious infection," respond:

- "Patient has completed pneumococcal (PPSV23 and PCV13/15/20), zoster (Shingrix), and annual influenza vaccines per CDC and ACR guidelines for immunosuppressed patients. Vaccine record attached."

- "Patient's last serious infection was [date, >6 months ago], treated successfully with [antibiotic]. TB screening (QuantiFERON or PPD) negative [date]. Hepatitis B/C serology negative. No current infection. Biologics are not contraindicated."

- Include vaccine and TB screening documentation.

4. For hypertension concerns with Lupkynis: Write:

- "Patient's blood pressure is controlled on [lisinopril + amlodipine]; home BP log average 128/78. Voclosporin can cause hypertension, but this is manageable with medication adjustment and close monitoring. The AURA-LV trial included patients with controlled hypertension. Denial on this basis is not supported by the evidence or FDA label."

5. Request your physician explicitly state there is no contraindication. The appeal letter should include: "I have reviewed the risks of [drug] with the patient, including [specific concern]. There is no absolute contraindication. The benefits (renal preservation, steroid sparing, prevention of ESRD) outweigh the risks, which will be mitigated by [monitoring plan]."

What We Do

We write evidence-based insurance appeals for patients and physicians fighting lupus treatment denials. We know which guidelines, trials, and arguments move insurers—EULAR 2023/2025, KDIGO 2024, BLISS-LN, AURA-LV, and the clinical rationale for early combination therapy—and we draft letters and peer-to-peer prep documents that cite them precisely. If your rheumatologist or nephrologist is too busy to write a detailed appeal, or if your first appeal was denied, we provide the level of documentation and argumentation that wins on second-level review or external appeal. We don't guarantee outcomes, but we do guarantee that your case will be presented with the full weight of current evidence.

Sources

1. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-723. [Updated 2023 and 2025; consult latest EULAR website for full text.]

2. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-745. [Updated 2023; see EULAR 2023 guidelines.]

3. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney Int. 2024;105(4S):S1-S69.

4. Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117-1128. [BLISS-LN]

5. Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070-2080. [AURA-LV]

6. Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl Med. 2020;382(3):211-221. [AURORA 1]

7. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215-1226. [LUNAR]

8. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222-233. [EXPLORER]

9. American College of Rheumatology. Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. *Arthritis Rheumatol.